8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported) – July 7, 2009

________________________

WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

_____________________

Pennsylvania	1-8036	23-1210010
(State or other jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
101 Gordon Drive, PO Box 645, Lionville, PA		19341-0645
(Address of principal executive offices)		(Zip Code)

(610) 594-2900

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or address, if changed since last report)

____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01    Regulation FD Disclosure.

West announced on July 7, 2009 that it had completed the purchase of the drug delivery device business assets of Plastef Investissements SA. A copy of the press release announcing the acquisition is attached to this report as Exhibit 99.1.

The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under that Act or the Securities Act of 1933.

 Item 9.01   Financial Statements and Exhibits

(d)	Exhibits
	Exhibit #	Description
	99.1	West Pharmaceutical Services, Inc. Press Release, dated July 7, 2009.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WEST PHARMACEUTICAL SERVICES, INC.

/s/ John R. Gailey III                                                         

John R. Gailey III Vice President, General

Counsel and Secretary

July 7, 2009

3

EXHIBIT INDEX

Exhibit No.	Description
99.1	West Pharmaceutical Services, Inc. Press Release, dated July 7, 2009.

4

EX-99.1

                   ; Exhibit 99.1

Contacts: West Michael A. Anderson Vice President and Treasurer (610) 594-3345 Investors and Financial Media: FD Evan Smith / Theresa Kelleher (212) 850-5600 wst@fd.com

WEST ACQUIRES DRUG DELIVERY ASSETS FROM PLASTEF INVESTISSEMENTS SA

Lionville, PA July 7, 2009 - West Pharmaceutical Services, Inc. (NYSE:WST) today announced that it has purchased the drug delivery device business assets of Plastef Investissements SA. Under the agreement West has obtained the right to manufacture the érissafety syringe, a passive safety system for use with fixed, or staked, needle prefillable syringes. Operations will continue at Plastef’s production facility located in Le Vaudreuil, Normandy, France, which has approximately 75 employees.

The éris system for staked needle syringes complements West’s NovaGuard™ passive safety needle, which it recently introduced to the market for use with luer-lock syringes.

Financial terms of the transaction were not disclosed. The acquisition is expected to increase West’s sales revenue by an estimated $5 million to $7 million over the remainder of 2009, and the acquisition is not expected to materially affect the Company’s fully diluted earnings per share this year.

About West

West is a global manufacturer of components and systems for injectable drug delivery, including stoppers and seals for vials, and closures and disposable components used in syringe, IV and blood collection systems. The Company also provides products with application to the personal care, food and beverage markets. Headquartered in Lionville, Pennsylvania, West supports its partners and customers from 50 locations throughout North America, South America, Europe, Mexico, Japan, Asia and Australia. For more information, visit West at www.westpharma.com.